These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 1581419

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T, Figari IS, Ranges GE, Palladino MA.
    J Immunol; 1988 Apr 01; 140(7):2312-6. PubMed ID: 3280680
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Nat Immun Cell Growth Regul; 1990 Apr 01; 9(4):283-96. PubMed ID: 2215516
    [Abstract] [Full Text] [Related]

  • 5. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Anticancer Res; 1990 Apr 01; 10(2A):441-6. PubMed ID: 2346317
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L, Weidmann E, Bungert B, Hechler P, Mitrou PS.
    Nat Immun Cell Growth Regul; 1990 Apr 01; 9(4):265-73. PubMed ID: 2120581
    [Abstract] [Full Text] [Related]

  • 8. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 01; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 9. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
    Chong AS, Scuderi P, Grimes WJ, Hersh EM.
    J Immunol; 1989 Mar 15; 142(6):2133-9. PubMed ID: 2493506
    [Abstract] [Full Text] [Related]

  • 10. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Production and regulation of interleukin 6 in human B lymphoid cells.
    Hutchins D, Cohen BB, Steel CM.
    Eur J Immunol; 1990 May 15; 20(5):961-8. PubMed ID: 2113479
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.
    Jelinek DF, Lipsky PE.
    J Immunol; 1987 Nov 01; 139(9):2970-6. PubMed ID: 3117883
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC, Juretic A, Schultz-Thater E, Dellabona P, Filgueira L, Hörig H, Zuber M, Garotta G, Heberer M.
    Cell Immunol; 1993 Feb 01; 146(2):391-405. PubMed ID: 8174177
    [Abstract] [Full Text] [Related]

  • 16. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL, Weaver AM, Brinckerhoff LH, Deacon DH, Gonias SL, Slingluff CL.
    J Immunother; 1998 Mar 01; 21(2):85-94. PubMed ID: 9551359
    [Abstract] [Full Text] [Related]

  • 17. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
    Han X, Itoh K, Balch CM, Pellis NR.
    Lymphokine Res; 1988 Mar 01; 7(3):227-35. PubMed ID: 3263554
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB, Gutterman JU, Grimm EA.
    Cancer Res; 1988 Feb 15; 48(4):788-92. PubMed ID: 3257408
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.